News

The collaboration will combine the immuno-oncology expertise and pipeline of Kyn Therapeutics with the capabilities of Celgene in development and commercialization of drugs in areas of high unmet

In accordance with Zymeworks’ 2014 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$8.0 million for Lilly’s submission of an IND application for

In June 2015, Vaccinex, the Huntington Study Group (HSG), and the University of Rochester’s Clinical Trials Coordination Center (CTCC) launched SIGNAL, the first clinical trial to investigate a

ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been

Under the deal, Spectrum will secure $160m in an upfront cash payment, while up to $140m in regulatory and sales-based milestones. Spectrum Pharmaceuticals president and CEO Joe Turgeon

Erleada is a next generation oral androgen receptor inhibitor approved to treat adult patients with nmCRPC who are at high risk of developing metastatic disease. Apalutamide holds capacity

This is the first time that a multinational pharmaceutical company has gained exclusive authorization in China to promote an innovative drug independently developed by a Chinese pharmaceutical company.

Juvenescence intends to complete its $100 million Series B financing with the closing of a second tranche in Q1 2019. Juvenescence has now raised over $110 million in

Through the investment, Schott plans to expand its primary business of glass tubing, used as the starting material for pharmaceutical packaging, and also pharmaceutical packaging made of glass and